Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,204.81
(
-1.08%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 79035

Thursday, 06/04/2009 5:50:18 PM

Thursday, June 04, 2009 5:50:18 PM

Post# of 257580
Strike Three for TLR’s in HCV!

Can investors now conclude that TLR’s are not the way to go in treating HCV? Let’s recap the progress to date:

• Jan 2007: Coley Pharmaceuticals drops Actilon, a TLR9 agonist that did not have much efficacy (#msg-16403804). Strike one.

• Jul 2007: ANDS discontinues ANA975, a TLR7 agonist that showed unacceptable liver toxicity (#msg-21600252). Strike two.

• Today: ANDS cans ANA773, a TLR7 agonist that’s the son of ANA975 (#msg-38418158). Strike three—you’re out!

If anyone thinks TLR’s still have a place in the treatment of HCV, speak now or forever hold your peace!


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today